U.S. Markets open in 8 hrs 26 mins
  • S&P Futures

    4,632.50
    -22.25 (-0.48%)
     
  • Dow Futures

    35,731.00
    -65.00 (-0.18%)
     
  • Nasdaq Futures

    15,432.75
    -163.00 (-1.05%)
     
  • Russell 2000 Futures

    2,149.60
    -8.10 (-0.38%)
     
  • Crude Oil

    85.12
    +1.30 (+1.55%)
     
  • Gold

    1,815.10
    -1.40 (-0.08%)
     
  • Silver

    22.94
    +0.03 (+0.12%)
     
  • EUR/USD

    1.1399
    -0.0012 (-0.1026%)
     
  • 10-Yr Bond

    1.7720
    0.0000 (0.00%)
     
  • Vix

    19.19
    -1.12 (-5.51%)
     
  • GBP/USD

    1.3637
    -0.0010 (-0.0736%)
     
  • USD/JPY

    114.8330
    +0.2530 (+0.2208%)
     
  • BTC-USD

    42,139.44
    -536.80 (-1.26%)
     
  • CMC Crypto 200

    1,009.59
    -16.14 (-1.57%)
     
  • FTSE 100

    7,611.23
    +68.28 (+0.91%)
     
  • Nikkei 225

    28,266.55
    -66.97 (-0.24%)
     

Surmodics Reports Fourth Quarter Fiscal 2021 Results and Issues Fiscal 2022 Revenue and EPS Guidance

  • Oops!
    Something went wrong.
    Please try again later.
·16 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

EDEN PRAIRIE, Minn., November 10, 2021--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 fourth quarter ended September 30, 2021 and provided its financial outlook for its fiscal 2022.

Summary of Fourth Quarter and Recent Highlights

  • Revenue of $24.0 million, an increase of 6% year-over-year

  • GAAP EPS of $(0.02), non-GAAP EPS of $(0.10)

  • Successful first patient use Sublime™ .018 RX PTA Dilatation Catheter

"We’re extremely pleased to share that the Sublime™ and Pounce™ clinical product evaluations are confirming the meaningful advantages of our radial access and arterial thrombectomy products," said Gary Maharaj, President and CEO of Surmodics, Inc. "Our fiscal 2022 promises to be an exciting year as we accelerate the commercialization of our innovative radial access, thrombectomy and drug-coated balloon platforms."

Fourth Quarter Fiscal 2021 Financial Results

Total revenue for the fourth quarter of fiscal 2021 was $24.0 million, compared to $22.5 million in the prior-year period. Medical Device revenue was $17.4 million for the fourth quarter of fiscal 2021, compared to $17.2 million for the prior-year period, an increase of 1%. Medical Device revenue in the fourth quarter of fiscal 2021 includes $1.2 million from our Development and Distribution Agreement with Abbott Vascular, Inc. ("Abbott") for the SurVeil™ drug-coated balloon, compared to $1.6 million in the prior-year quarter. In Vitro Diagnostics revenue was $6.6 million for the fourth quarter of fiscal 2021, compared to $5.4 million in the same prior-year quarter, an increase of 23%.

Diluted GAAP earnings per share in the fourth quarter of fiscal 2021 was a loss per share of $(0.02), compared to a loss per share of $(0.22) in the prior-year period. On a non-GAAP basis, loss per share in the fourth quarter of fiscal 2021 was $(0.10), compared to a loss per share of $(0.18) in the same prior-year quarter. On a non-GAAP basis, adjusted net loss and adjusted EPS exclude a $2.6 million and $0.19 per share tax-effected benefit, respectively, recorded in the fourth quarter of fiscal 2021 related to the reimbursement of certain expenses under the employee retention credit provisions of the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act").

As of September 30, 2021, Surmodics reported cash and investments totaling $40.9 million and $10 million in outstanding borrowings on its $25 million line of credit. Surmodics reported $0.9 million of cash provided by operating activities and $2.4 million in capital expenditures in the fourth quarter of fiscal 2021. Surmodics completed its acquisition of Vetex Medical Limited during the fourth quarter of fiscal 2021, with the upfront cash payment of $39.9 million funded using cash on hand and $10 million from the Company’s $25 million line of credit.

Fiscal 2022 Guidance

Surmodics has the potential to receive a $30 million milestone payment during fiscal 2022 related to premarket approval of the SurVeil DCB pursuant to the Abbott Development and Distribution Agreement. The potential revenue associated with this milestone payment would be approximately $25 million. As has been the Company’s practice with past guidance, revenue from regulatory-related milestones is not included in guidance until they are achieved.

Surmodics expects fiscal year 2022 revenue to range from $97 million to $101 million. The Company expects fiscal 2022 diluted GAAP EPS to range from a loss per share of $(2.05) to $(1.55), which reflects increased investments to accelerate the Company’s strategy. Non-GAAP diluted EPS for fiscal 2022 is expected to range from a loss per share of $(1.75) to $(1.25).

Conference Call Today at 7:30 a.m. CT (8:30 a.m. ET)

Surmodics is hosting a webcast at 7:30 a.m. CT (8:30 a.m. ET) today to discuss fourth quarter results. To access the webcast, go to the investor relations portion of the Company’s website at https://surmodics.gcs-web.com and click on the webcast icon. The webcast will be archived on the Company’s website for 90 days. A replay of the fourth quarter conference call will be available by dialing 888-203-1112 and entering conference call ID passcode 2633660. The audio replay will be available beginning at 10:30 a.m. CT on Wednesday, November 10, 2021, until 10:30 a.m. CT on Wednesday, November 17, 2021.

About Surmodics, Inc.

Surmodics is a leading provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing development and commercialization of highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface technologies, along with enhanced device design, development, and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the Company makes with the Securities and Exchange Commission ("SEC").

Safe Harbor for Forward-looking Statements

This press release, and disclosures related to it, contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical or current facts, including statements regarding the Company’s revenue and loss expectations for fiscal 2022; expectations regarding acceleration of the commercialization of the Company’s radial access, thrombectomy and drug-coated balloon platforms; expectations regarding design verification, process validation, and manufacturing validation related to the Company’s products; our fiscal 2022 objectives; expectations regarding expansion of the potential range of uses of the Company’s products; the potential market position of the Company’s products; the anticipated fiscal 2022 full-year license revenue associated with the Development and Distribution Agreement with Abbott; expectations regarding FDA premarket review timing and process and the potential approval of our SurVeil DCB; the potential receipt of a premarket approval milestone payment from Abbott; the expected timing of completion and delivery of the SWING first-in-human clinical trial results; the potential of the Company’s products and fiscal 2022 activities to create long-term value; the Company’s strategy; plans for clinical product evaluations; the anticipated reimbursement under CARES Act Employee Retention Credit; expectations regarding revenue from our Sublime and Pounce product portfolios and growth in the value of those portfolios; and expectations regarding fiscal 2022 revenue growth, operating expenses and tax expense, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including, without limitation: (1) our ability to successfully develop and commercialize our SurVeil DCB (including realization of the full potential benefits of our agreement with Abbott), Avess™ DCB, Sundance™ DCB, and other proprietary products; (2) whether and when the FDA grants premarket approval to the SurVeil DCB; (3) our reliance on third parties (including our customers and licensees) and their failure to successfully develop, obtain regulatory approval for, market, and sell products incorporating our technologies; (4) possible adverse market conditions and possible adverse impacts on our cash flows; (5) the impacts, duration, and severity of the global COVID-19 pandemic and the effects of responses to it on healthcare systems, the general economy, our business partners, and our operations; (6) our ability to integrate the acquisition of Vetex Medical Limited successfully and realize the anticipated benefits of the acquisition; and (7) the factors identified under "Risk Factors" in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and subsequent SEC filings. These reports are available in the Investors section of our website at https://surmodics.gcs-web.com and at the SEC website at www.sec.gov. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.

Use of Non-GAAP Financial Information

In addition to reporting financial results in accordance with U.S. generally accepted accounting principles, or GAAP, Surmodics is reporting non-GAAP financial results including EBITDA and Adjusted EBITDA, non-GAAP operating (loss) income, non-GAAP operating (loss) income percentage, non-GAAP (loss) income before income taxes, non-GAAP net (loss) income, non-GAAP diluted (loss) earnings per share, and the non-GAAP effective income tax rate. We believe that these non-GAAP measures, when read in conjunction with the Company’s GAAP financial statements, provide meaningful insight into our operating performance excluding certain event-specific matters, and provide an alternative perspective of our results of operations. We use non-GAAP measures, including those set forth in this release, to assess our operating performance and to determine payouts under our executive compensation programs. We also are providing guidance on a range of non-GAAP diluted loss per share for fiscal 2022. We believe that presentation of certain non-GAAP measures allows investors to review our results of operations from the same perspective as management and our board of directors and facilitates comparisons of our current results of operations. The method we use to produce non-GAAP results is not in accordance with GAAP and may differ from the methods used by other companies. Non-GAAP results should not be regarded as a substitute for corresponding GAAP measures but instead should be utilized as a supplemental measure of operating performance in evaluating our business. Non-GAAP measures do have limitations in that they do not reflect certain items that may have a material impact on our reported financial results. As such, these non-GAAP measures should be viewed in conjunction with both our financial statements prepared in accordance with GAAP and the reconciliation of the supplemental non-GAAP financial measures to the comparable GAAP results provided for the specific periods presented, which are attached to this release.

Surmodics, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(in thousands, except per share data)

(Unaudited)

Three Months Ended

Fiscal Year Ended

September 30,

September 30,

2021

2020

2021

2020

Revenue:

Product sales

$

12,509

$

10,586

$

46,478

$

44,317

Royalties and license fees

8,874

9,867

47,056

40,634

Research, development and other

2,588

2,090

11,602

9,913

Total revenue

23,971

22,543

105,136

94,864

Operating costs and expenses:

Product costs

4,159

3,902

17,177

15,317

Research and development

10,731

12,787

46,734

50,188

Selling, general and administrative

7,865

7,300

30,680

28,392

Acquired intangible asset amortization

1,117

547

2,793

2,218

Acquisition transaction, integration and other costs

588

1,049

Total operating costs and expenses

24,460

24,536

98,433

96,115

Operating (loss) income

(489

)

(1,993

)

6,703

(1,251

)

Other expense, net

(73

)

(85

)

(357

)

(203

)

(Loss) income before income taxes

(562

)

(2,078

)

6,346

(1,454

)

Income tax benefit (provision)

273

(868

)

(2,109

)

2,577

Net (loss) income

$

(289

)

$

(2,946

)

$

4,237

$

1,123

Basic (loss) income per share:

$

(0.02

)

$

(0.22

)

$

0.31

$

0.08

Diluted (loss) income per share:

$

(0.02

)

$

(0.22

)

$

0.30

$

0.08

Weighted average number of shares outstanding:

Basic

13,851

13,639

13,765

13,552

Diluted

13,851

13,639

13,989

13,812

Surmodics, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands)

September 30,

2021

2020

Assets

Current Assets:

Cash and cash equivalents

$

31,153

$

30,785

Available-for-sale securities

7,717

30,313

Accounts receivable, net

9,169

7,675

Contract assets — royalties and license fees

7,091

6,108

Inventories, net

6,760

5,966

Prepaids and other

8,365

5,761

Total Current Assets

70,255

86,608

Property and equipment, net

30,090

30,103

Available-for-sale securities

2,002

Deferred income taxes

5,867

7,315

Intangible assets, net

37,054

13,283

Goodwill

45,606

27,185

Other assets

3,718

4,269

Total Assets

$

194,592

$

168,763

Liabilities and Stockholders’ Equity

Current Liabilities:

Short-term borrowings

10,000

Deferred revenue

4,647

5,200

Other current liabilities

15,168

13,692

Total Current Liabilities

29,815

18,892

Deferred revenue

10,301

10,796

Other long-term liabilities

14,391

8,020

Total Liabilities

54,507

37,708

Total Stockholders’ Equity

140,085

131,055

Total Liabilities and Stockholders’ Equity

$

194,592

$

168,763

Surmodics, Inc. and Subsidiaries

Supplemental Segment Information

(in thousands)

(Unaudited)

Three Months Ended September 30,

2021

2020

Revenue:

% of Total

% of Total

% Change

Medical Device

$

17,395

72.6%

$

17,179

76.2%

1.3%

In Vitro Diagnostics

6,576

27.4%

5,364

23.8%

22.6%

Total revenue

$

23,971

$

22,543

6.3%

Fiscal Year Ended September 30,

2021

2020

Revenue:

% of Total

% of Total

% Change

Medical Device

$

78,253

74.4%

$

71,401

75.3%

9.6%

In Vitro Diagnostics

26,883

25.6%

23,463

24.7%

14.6%

Total revenue

$

105,136

$

94,864

10.8%

Three Months Ended

Fiscal Year Ended

September 30,

September 30,

2021

2020

2021

2020

Operating (loss) income:

Medical Device

$

(797

)

$

(1,902

)

$

4,683

$

(3,246

)

In Vitro Diagnostics

3,363

2,456

13,770

11,771

Total segment operating income

2,566

554

18,453

8,525

Corporate

(3,055

)

(2,547

)

(11,750

)

(9,776

)

Total (loss) income from operations

$

(489

)

$

(1,993

)

$

6,703

$

(1,251

)

Surmodics, Inc. and Subsidiaries

Reconciliation of GAAP Measures to Non-GAAP Amounts

Schedule of EBITDA, Adjusted EBITDA and Cash Flows from Operations

(in thousands)

(Unaudited)

Three Months Ended

Fiscal Year Ended

September 30,

September 30,

2021

2020

2021

2020

Net (loss) income

$

(289

)

$

(2,946

)

$

4,237

$

1,123

Income tax (benefit) provision

(273

)

868

2,109

(2,577

)

Depreciation and amortization

2,407

1,873

8,017

7,263

Investment income, net

(28

)

(72

)

(123

)

(656

)

Interest expense

132

34

310

133

EBITDA

1,949

(243

)

14,550

5,286

Adjustments:

Acquisition transaction, integration and other costs (1)

588

1,049

CARES Act Employee Retention Credit (2)

(3,577

)

(3,577

)

Loss on strategic investment (3)

479

Adjusted EBITDA

$

(1,040

)

$

(243

)

$

12,022

$

5,765

Net Cash Provided by Operating Activities

$

889

$

1,314

$

15,389

$

14,010

Guidance Reconciliation: Estimated Non-GAAP Diluted Earnings Per Share

For the Fiscal Year Ending September 30, 2022

(Unaudited)

Fiscal 2022 Full-Year Estimate

Low

High

GAAP diluted EPS

$

(2.05

)

$

(1.55

)

Amortization of acquired intangibles per diluted share (4)

0.30

0.30

Non-GAAP diluted EPS

$

(1.75

)

$

(1.25

)

Surmodics, Inc., and Subsidiaries

Net Loss and Diluted EPS GAAP to Non-GAAP Reconciliation

(in thousands, except per share data)

(Unaudited)

For the Three Months Ended September 30, 2021

Total
Revenue

Operating
Loss

Operating
Loss
Percentage

Loss
Before
Income
Taxes

Net
Loss
(6)

Diluted
EPS
(7)

Effective
tax rate

GAAP

$

23,971

$

(489

)

(2.0

)%

$

(562

)

$

(289

)

$

(0.02

)

48.6

%

Adjustments:

Amortization of acquired intangible assets (4)

1,117

4.7

%

1,117

1,014

0.07

Acquisition transaction, integration and other costs (1)

588

2.4

%

588

554

0.04

CARES Act Employee Retention Credit (2)

(3,577

)

(14.9

)%

(3,577

)

(2,617

)

(0.19

)

Non-GAAP

$

23,971

$

(2,361

)

(9.8

)%

$

(2,434

)

$

(1,338

)

$

(0.10

)

45.0

%

For the Three Months Ended September 30, 2020

Total
Revenue

Operating
Loss

Operating
Loss
Percentage

Loss
Before
Income
Taxes

Net
Loss
(6)

Diluted
EPS
(7)

Effective
tax rate

GAAP

$

22,543

$

(1,993

)

(8.8

)%

$

(2,078

)

$

(2,946

)

$

(0.22

)

(41.8

)%

Adjustments:

Amortization of acquired intangible assets (4)

547

2.4

%

547

517

0.04

Non-GAAP

$

22,543

$

(1,446

)

(6.4

)%

$

(1,531

)

$

(2,429

)

$

(0.18

)

(58.7

)%

Surmodics, Inc., and Subsidiaries

Net Income and Diluted EPS GAAP to Non-GAAP Reconciliation

(in thousands, except per share data)

(Unaudited)

Fiscal Year Ended September 30, 2021

Total
Revenue

Operating
Income

Operating
Income
Percentage

Income
Before
Income
Taxes

Net
Income
(6)

Diluted
EPS

Effective
tax rate

GAAP

$

105,136

$

6,703

6.4

%

$

6,346

$

4,237

$

0.30

33.2

%

Adjustments:

Amortization of acquired intangible assets (4)

2,793

2.7

%

2,793

2,600

0.19

Acquisition transaction, integration and other costs (1)

1,049

1.0

%

1,049

1,015

0.07

CARES Act Employee Retention Credit (2)

(3,577

)

(3.5

)%

(3,577

)

(2,617

)

(0.19

)

Non-GAAP

$

105,136

$

6,968

6.6

%

$

6,611

$

5,235

$

0.37

20.8

%

Fiscal Year Ended September 30, 2020

Total
Revenue

Operating
(Loss)
Income

Operating
(Loss)
Income
Percentage

(Loss)
Income
Before
Income
Taxes

Net
Income
(6)

Diluted
EPS

Effective
tax rate

GAAP

$

94,864

$

(1,251

)

(1.3

)%

$

(1,454

)

$

1,123

$

0.08

177.2

%

Adjustments:

Amortization of acquired intangible assets (4)

2,218

2.3

%

2,218

2,076

0.15

Loss on strategic investment (3)

479

378

0.03

Discrete tax impact of CARES Act (5)

(1,768

)

(0.13

)

Non-GAAP

$

94,864

$

967

1.0

%

$

1,243

$

1,809

$

0.13

(45.5

)%

(1)

Represents expenses specifically associated with the business acquisition of Vetex Medical Limited and associated tax impact. A significant proportion of the acquisition expenses are not tax deductible.

(2)

Represents the benefit recorded as a result of the employee retention credit that the Company filed for under the provisions of the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") enacted in March 2020. The estimated tax impact reflects the combined impact of the statutory tax rate of 21% and a reduction in research and development tax credits.

(3)

In fiscal 2020, represents the loss recognized on the impairment of a strategic investment and associated tax impact.

(4)

Amortization of business acquisition-related intangible assets and associated tax impact. A significant portion of the business acquisition-related amortization is not tax deductible.

(5)

Represents the discrete income tax benefit recognized in fiscal 2020 from the carryback of net operating losses under the provisions of the CARES Act.

(6)

Net (loss) income includes the effect of the above adjustments on the income tax benefit (provision), taking into account deferred taxes and non-deductible items. Income tax impacts were estimated using the applicable statutory rate (21% in the U.S. and 12.5% in Ireland).

(7)

Potentially dilutive common shares resulting from dilutive common stock options and non-vested stock relating to restricted stock awards and restricted stock units have been excluded from the calculation of GAAP net loss per share as their effect was antidilutive for three months ended September 30, 2021 and 2020 as a result of the GAAP net loss for these periods.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005421/en/

Contacts

Surmodics, Inc.
Tim Arens, 952-500-7000
ir@surmodics.com